CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 931 - 940 of 1139
Study Number Lead Group Study Title CIRB Study Status
AALL07P1 COG A Phase II Pilot Trial of Bortezomib (PS-341; Velcade; IND# 58;443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) Pediatric CIRB Completed
ADVL1521 COG A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia Pediatric CIRB Available to Open
ACNS1721 COG A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations Pediatric CIRB Available to Open
ACNS1831 COG A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Pediatric CIRB Available to Open
AALL0433 COG Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies. A Groupwide Phase III Study Pediatric CIRB Completed
ACCL1031 COG A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation: A Groupwide Phase III Study Pediatric CIRB Completed
ARET0332 COG A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Groupwide Phase III Study Pediatric CIRB Completed
AOST1421 COG A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab; NSC# 764038; IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma Pediatric CIRB Available to Open
ACNS1931 COG A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Pediatric CIRB Available to Open
PBTC-058 PBTC Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma Pediatric CIRB Available to Open
Displaying 931 - 940 of 1139